Tests milsaperidone added to usual treatment for major depressive disorder
Tests milsaperidone or placebo added to usual care in adults with depression.
Plain-language title generated from the registry record
Registry title: Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Key facts
- Where
- Berlin, Chemnitz, and Stralsund, GermanySee the 4 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06830044, who can take part
Where in Germany
- FutureMeds GmbHBerlin, GermanyNot yet recruiting
- Praxis Dr. med. Kirsten HahnBerlin, GermanyNot yet recruiting
- Pharmakologisches Studienzentrum Chemnitz GmbHChemnitz, GermanyNot yet recruiting
- Facharzt für Psychiatrie und PsychotherapieStralsund, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vanda Pharmaceuticals
- Trial code
- NCT06830044EU 2024-520333-68-00
- Record updated
- 24 September 2026
- Original description
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive DisorderRead full original descriptionShow less
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Milsaperidone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder
Inclusion: Male or female patient 18 to 65 years of age, inclusive; Meets DSM-5-TR criteria for MDD; Currently having an inadequate response to antidepressant therapy as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ).
Exclusion: Within the patients lifetime, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD; Within 6 months of Screening, has a confirmed DSM-5-TR psychiatric diagnosis other than MDD; Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment.